| 000 | 01600 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250517171418.0 | ||
| 264 | 0 | _c20180822 | |
| 008 | 201808s 0 0 eng d | ||
| 022 | _a1941-837X | ||
| 024 | 7 |
_a10.1080/13696998.2017.1372222 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _avan Hulst, Marinus | |
| 245 | 0 | 0 |
_aThe cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands. _h[electronic resource] |
| 260 |
_bJournal of medical economics _cJan 2018 |
||
| 300 |
_a38-46 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 |
_aAntithrombins _xeconomics |
| 650 | 0 | 4 |
_aAtrial Fibrillation _xcomplications |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aCost-Benefit Analysis _xeconomics |
| 650 | 0 | 4 |
_aDabigatran _xeconomics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMarkov Chains |
| 650 | 0 | 4 | _aNetherlands |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 |
_aThromboembolism _xetiology |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVitamin K _xadministration & dosage |
| 700 | 1 | _aStevanovic, Jelena | |
| 700 | 1 | _aJacobs, Maartje S | |
| 700 | 1 | _aTieleman, Robert G | |
| 700 | 1 | _aKappelhoff, Bregt | |
| 700 | 1 | _aPostma, Maarten J | |
| 773 | 0 |
_tJournal of medical economics _gvol. 21 _gno. 1 _gp. 38-46 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/13696998.2017.1372222 _zAvailable from publisher's website |
| 999 |
_c27493777 _d27493777 |
||